Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
We report the use of rituximab (Genentech, San Francisco, CA, USA) in two children with severe haemophilia with inhibitors to factors VIII and IX, which failed to respond to conventional immune tolerance therapy. The treatment was well tolerated by both children. The child with haemophilia B had no clinical improvement or fall in CD19 and he is currently being treated with recombinant activated factor VII (NovoSeven, Novo Nordisk, Denmark) for bleeding episodes. The child with haemophilia A had a good clinical response with a negative inhibitor assay at 11 months follow-up.
Mathias
Mary
M
Haemophilia Centre, Great Ormond Street Children's Hospital, London, UK.
Khair
Kate
K
Hann
Ian
I
Liesner
Ri
R
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood; D002675:Child, Preschool; D005164:Factor IX / Q000276:immunology*; D005169:Factor VIII / Q000276:immunology*; D006467:Hemophilia A / Q000188:drug therapy*; D002836:Hemophilia B / Q000188:drug therapy*; D006801:Humans; D007108:Immune Tolerance; D007518:Isoantibodies / Q000097:blood; D008297:Male; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D019774:Blood Coagulation Factor Inhibitors; D007518:Isoantibodies; D000069283:Rituximab; D005169:Factor VIII; D005164:Factor IX